Retatrutide

01 · What it is

Retatrutide is the first compound in this project for which someone has published a chemical analysis of what is actually being sold under its name — and that paper exists precisely because the compound is not approved and is being sold anyway.

The paper is Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia, in Drug and Alcohol Review ²⁸. This guide has not read its findings. PubMed carries no abstract for it, and this guide does not report results it has not seen. What can be said is that a peer-reviewed journal published an analysis of consumer-market retatrutide products in 2026, which is a category of evidence that did not exist for any of the fifty-eight compounds covered before this one. Retrieving its full text is the highest-priority verification item attached to this guide.

The evidence for the compound itself is thinner than its reputation. Retatrutide is a triple agonist at the GLP-1, GIP and glucagon receptors, described in a 2026 review as undergoing clinical trials for obesity and diabetes ²⁷. A systematic review and meta-analysis of randomised trials exists ⁵, as do Bayesian and frequentist network meta-analyses ^9,13, and qualitative exit interviews with phase 2 participants ^8,11. This guide did not retrieve the primary phase 2 trial publication itself, across two searches; that is a gap in this search rather than a claim that none exists, and it is flagged below.

The headline figure and the pooled figure do not agree. A 2026 review states the triple agonist produced weight reductions exceeding 25% ¹⁷; a dermatology review cites up to 24.2% in phase 2 ²³; a 2025 systematic review of the whole obesity pipeline gives completed phase 2 incretin trials a range of 7.4% to 24.2% ³. Against those, the 2026 BMJ network meta-analysis places retatrutide among emerging agents producing reductions of 13.1% to 14.6%, at very low to low certainty ¹⁵. The gap between “exceeding 25%” and “13.1–14.6% at very low certainty” is not a rounding difference. It is the difference between a best dose arm in a selected trial and a pooled estimate with its uncertainty stated.

Three 2026 items in the BMJ and European Journal of Internal Medicine concern harm and access, not efficacy: a fact-check asking whether a man died after taking the unapproved compound ¹⁶, a report that it opened to compassionate use in the US ²⁴, and a commentary on a urinary tract infection signal ¹⁹. Their existence is the point; this guide reports their questions, not answers it has not read.

02 · Evidence at a glance

Evidence grade

Early Clinical — randomised human trials exist and are pooled in meta-analyses; no marketing authorisation

Approval status

None. Described as undergoing clinical trials ²⁷

What it is

An injectable peptide agonist of the GLP-1, GIP and glucagon receptors ²⁷

Primary phase 2 publication

Not retrieved in this search — see limitations

Systematic review and meta-analysis of RCTs

Yes ⁵

Network meta-analyses

Bayesian ⁹; frequentist ¹³; pipeline-wide ¹⁵

Headline weight figure

Exceeding 25% per one 2026 review ¹⁷; up to 24.2% in phase 2 per another ²³

Pooled weight figure

13.1–14.6%, very low to low certainty, in the BMJ network meta-analysis ¹⁵

Phase 2 range for the class

7.4% to 24.2% across completed phase 2 incretin trials ³

Blood pressure and lipids

Meta-analysis of randomised trials ¹⁴

Cardiovascular risk biomarkers

Yes — two studies, 36 and 48 weeks ²⁵. Biomarkers, not events

Cardiovascular outcome trial

None located

Liver fat

Reductions of roughly 60–80% attributed to glucagon-containing agents in a 2026 review ²²

Preclinical

Diet-induced obese MASH mouse and hamster models ¹²; rodent cognition ²⁹

Patient-reported research

Exit interviews from a phase 2 trial ⁸; a scale developed from them ¹¹

Analysis of consumer-market product

Published ²⁸ — findings not read by this guide

Analytical method for the class

Multiplexed LC-HRMS for nine GLP-1 receptor agonists ¹⁸

Harm and access items, 2026

Death fact-check ¹⁶; compassionate use ²⁴; urinary tract infection signal ¹⁹

03 · Mechanism of action

Three receptors, and the third is the novel one

Retatrutide agonises the GLP-1 receptor, the GIP receptor and the glucagon receptor ²⁷. The first two are the tirzepatide combination. The glucagon receptor is what makes this a different proposition, and the reason is that glucagon has historically been understood as the hormone that opposes insulin — a 2026 IUPHAR review is titled, precisely, From foe to friend: repurposing glucagon to treat obesity and type 2 diabetes ¹⁰.

Deliberately agonising the glucagon receptor to treat metabolic disease inverts a textbook relationship. That is either an elegant piece of pharmacology or a source of effects nobody has characterised at scale, and the published record does not yet settle which.

What glucagon agonism is claimed to add

A 2026 review attributes to glucagon-containing agents — naming survodutide and retatrutide — a preferential reduction in visceral and hepatic fat, with liver-fat reductions of roughly 60–80%, and characterises this as a difference in the quality of weight loss rather than only its quantity ²². The preclinical work in diet-induced obese MASH mouse and hamster models is consistent with a liver-directed effect ¹², and a meta-analysis of GLP-1-based polyagonists in steatotic liver disease places retatrutide in that group ²¹.

The liver claim is the mechanistically interesting one, because it is the place where adding the glucagon receptor would be expected to matter and where a distinct effect could be measured rather than assumed. It is also, at present, supported by reviews and preclinical models rather than by a retatrutide-specific randomised hepatic-outcome trial located here.

Where the receptor combination sits in the class

Historical and pharmacological reviews place retatrutide as the current end point of a progression from single- to dual- to triple-receptor agonism ^1,2,6,10,27, and a 2026 review of multi-agonism frames the design question as optimising weight and glycaemia while reducing gastrointestinal side effects ²¹.

That framing is worth keeping. The design problem in this class is not only how much weight comes off; it is how much of the effect can be had without the gastrointestinal cost that drives people to stop.

04 · Key research findings

Weight

Pipeline review, 2025. Completed phase 2 trials of incretin-based therapies showed mean percent weight loss of 7.4% to 24.2%, with almost half of drugs in phase 2 being incretin analogues ³.

Model-based meta-analysis, 2025. A comparison of GLP-1 receptor agonists for weight reduction across placebo-controlled trials ⁴.

Systematic review and meta-analysis, 2025. Efficacy and safety of retatrutide in patients with obesity with or without diabetes, drawing on randomised controlled trials from four databases searched to May 2024 ⁵.

Bayesian network meta-analysis, 2025. GLP-1 receptor agonists, dual agonists and retatrutide compared for weight loss in adults with overweight or obesity ⁹.

Network meta-analysis, 2026. Across incretin-based therapies in type 2 diabetes, retatrutide ranked best for weight loss, with tirzepatide, orforglipron and semaglutide best for glycaemic control ¹³.

BMJ network meta-analysis, 2026. Emerging agents — ecnoglutide, mazdutide and retatrutide — may produce similar or greater reductions than established agents, at 13.1% to 14.6%, rated very low to low certainty ¹⁵.

Future-of-treatment review, 2026. Tirzepatide, CagriSema and amycretin achieved reductions exceeding 20%, and retatrutide exceeding 25% ¹⁷.

The synthesis for this system: every number above is real and they do not describe the same quantity. The 25% figure is a trial result; the 13.1–14.6% figure is a pooled estimate carrying an explicit certainty rating of very low to low. A guide that reported only the first would be reporting the literature’s most flattering sentence and calling it the finding.

Cardiovascular and metabolic markers

Blood pressure and lipids, 2026. A systematic review and meta-analysis of randomised controlled trials, undertaken on the stated basis that the effect of the triple agonist on these markers remained to be elucidated ¹⁴.

Cardiovascular risk biomarkers, 2026. Two studies: in the first, adults with obesity or overweight and type 2 diabetes received once-weekly retatrutide, dulaglutide or placebo for 36 weeks; in the second, adults with clinical obesity without type 2 diabetes received retatrutide or placebo for 48 weeks. The doses administered in those protocols were 0.5, 4, 8 and 12 mg in the first and 1, 4, 8 and 12 mg in the second ²⁵.

Stated as the protocols used in that publication, and reported here only to characterise the design. The endpoint is biomarkers. No cardiovascular outcome trial was located, and biomarker improvement is not event reduction — a distinction this project has had to make in a dozen guides and which applies with full force here, because the compound has no completed outcome trial to fall back on.

Incretins as cardiovascular agents, 2026. A state-of-the-art review summarising the evidence across five clinical scenarios: type 2 diabetes with established atherosclerotic disease or high cardiovascular risk; overweight or obesity with established cardiovascular disease but without diabetes; obesity-related heart failure with preserved ejection fraction; and others ²⁰.

Retatrutide appears in that review as a member of the class, not as the subject of any of those five scenarios. The scenarios were defined by trials the approved agents ran.

Liver and preclinical

MASH polyagonist meta-analysis, 2026. Tirzepatide, survodutide, pemvidutide, retatrutide and cotadutide together significantly increased resolution of steatohepatitis or histological improvement without worsening of fibrosis (RR 3.32, 95% CI 2.28–4.84; I² = 20%) ²¹.

Note what that number is attached to. It is a pooled estimate across five different compounds, not a retatrutide result. Class-level pooling of distinct molecules is a useful signal and a poor substitute for compound-specific evidence.

Antiobesity medications in steatotic liver disease, 2025. A review covering the development, mode of action and available published data on effectiveness across approved and investigational agents in adult and paediatric obesity and metabolic dysfunction-associated steatotic liver disease ⁷.

Cited for what it is: a review that places retatrutide alongside approved agents in a summary of published data. It carries the compound’s liver claim into the review literature; it does not independently test it.

Preclinical models, 2026. Retatrutide showed multiple metabolic benefits in diet-induced obese MASH mouse and hamster models ¹².

Rodent cognition, 2026. Whether retatrutide attenuates learning and memory impairment in a streptozotocin-induced insulin-deficient diabetic rat model, in male Sprague-Dawley rats allocated to four groups ²⁹.

The synthesis: the liver signal has preclinical support in two species and class-level clinical support, and the cognition work is a single rodent study in a chemically induced diabetes model. These sit at very different distances from anything human.

Safety signals, access, and what is being sold

Urinary tract infection signal, 2026. A commentary in the European Journal of Internal Medicine asking whether the answer to a urinary tract infection signal is hidden in timing ¹⁹.

Death fact-check, 2026. A BMJ item asking whether a man died after taking the unapproved weight loss injection ¹⁶. PubMed carries no abstract; this guide has not read the item and reports only that the question was put in a major medical journal.

Compassionate use, 2026. A BMJ report that the drug opened to compassionate use in the US ²⁴.

Neuropsychiatric review, 2026. A Bradford Hill-informed systematic evaluation of the psychopharmacology and putative neuropsychiatric associations of GLP-1 and dual GIP/GLP-1 receptor agonists ²⁶.

Composition of consumer-market product, 2026. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia, in Drug and Alcohol Review ²⁸. No abstract is indexed and this guide has not read the findings.

Analytical capability, 2026. A rapid, sensitive and selective multiplexed LC-HRMS method, developed and validated for the identification and quantitation of nine structurally diverse peptide-based GLP-1 receptor agonists, with a stated pharmaceutical application ¹⁸.

The synthesis for this system, and the reason this guide leads on it: for most compounds in this project, the honest line is that nobody has analysed what is being sold. For retatrutide, somebody has, and the analytical methods to do it are being published in parallel ^18,28. That changes the character of the open question from “unknowable” to “published and not yet read here,” which is a better problem to have and a worse one to leave unresolved.

05 · Evidence overview

06 · Safety profile

This section reports the existence and structure of the safety literature. It does not enumerate adverse effects or offer guidance of any kind. For an unapproved compound there is no product label to defer to, which makes the gaps below more consequential rather than less.

Animal data. Metabolic effects in diet-induced obese MASH mouse and hamster models ¹² and a cognition study in streptozotocin-induced diabetic rats ²⁹. No dedicated toxicology study was retrieved in this search.

Human data. Safety was assessed within the randomised trials pooled by the 2025 systematic review ⁵ and the network meta-analyses ^9,13,15. A urinary tract infection signal has attracted published commentary ¹⁹. A class-wide review frames gastrointestinal adverse events as the problem the multi-agonist design is explicitly trying to reduce ²¹. Neuropsychiatric associations across the class have been evaluated systematically ²⁶.

The important qualification: all of it is pooled or class-level. This guide did not read a compound-specific primary safety report for retatrutide.

What is genuinely unknown. Four things, and they are not small.

Cardiovascular outcomes. No outcome trial was located. The available cardiovascular evidence is biomarker evidence ²⁵. For a compound whose nearest approved comparators have completed event-driven outcome trials, that is a substantial difference in evidentiary standing.

Long-term anything. The longest study described in the records examined here ran 48 weeks ²⁵.

Whether the death question has an answer. A BMJ fact-check put the question in 2026 ¹⁶. This guide has not read it, does not know the answer, and will not guess. That item alone justifies treating this compound’s safety position as open.

What is in the products. An analysis of consumer-market retatrutide products in Australia has been published ²⁸. Its findings are not in the abstract record and are not reported here. Until they are read, nothing can be said about the identity, purity, concentration or contamination of any retatrutide-labelled material sold outside a clinical trial.

07 · US regulatory status

Current as of 7 September 2026. Retatrutide holds no marketing authorisation and is described in the peer-reviewed literature as undergoing clinical trials ²⁷. A 2026 BMJ news report states that it opened to compassionate use in the United States ²⁴; compassionate-use access is a regulated pathway for an unapproved drug and is not an approval.

This guide has not consulted FDA records, trial registries beyond the identifier reported in a cited paper, or any regulatory document. No statement is made here about specific programmes, pathways or agency determinations beyond what the cited publications state.

Because the compound is unapproved, it cannot lawfully be supplied for human use in the United States outside an authorised clinical trial or a formal expanded-access pathway. It is being sold anyway — that is the premise of the Australian composition study ²⁸ and of the BMJ items ^16,24.

Under the World Anti-Doping Code, competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. This guide did not retrieve the primary phase 2 trial publication. Two PubMed searches returned meta-analyses, network meta-analyses, reviews and qualitative studies drawing on it ^5,8,9,11,13, but not the trial report itself. Everything this guide says about efficacy is therefore secondhand, through synthesis papers. This is the guide’s single largest weakness and is a search limitation, not evidence of absence.
2. The two most consequential citations have no abstract and have not been read. The composition study ²⁸ and the death fact-check ¹⁶ are both indexed without abstracts. This guide cites their existence and titles and reports nothing about their contents. Both require full-text retrieval before this guide is relied on.
3. The headline efficacy figure and the pooled estimate diverge by roughly a factor of two ^15,17. The pooled estimate carries a certainty rating of very low to low, assigned by its own authors ¹⁵. Any single number quoted for this compound should be read with that spread in view.
4. No cardiovascular outcome trial was located. The cardiovascular evidence is biomarkers at 36 and 48 weeks ²⁵. Biomarker improvement has repeatedly failed to predict event reduction across therapeutic areas, and there is nothing about this compound that exempts it from that history.
5. The liver figure is not a retatrutide figure. The 60–80% liver-fat reduction is attributed in a review to glucagon-containing agents as a group ²², and the RR 3.32 (95% CI 2.28–4.84) for steatohepatitis is pooled across five distinct compounds ²¹. Neither is compound-specific evidence.
6. No dedicated toxicology study was retrieved, so this guide reports no formal preclinical safety assessment.
7. The longest study described here is 48 weeks ²⁵. Nothing located addresses durability, maintenance, or what happens on stopping.
8. The patient-reported research is exit-interview and instrument-development work ^8,11, funded and conducted around a sponsor trial. It describes perceived benefit; it is not efficacy evidence and this guide does not treat it as such.
9. Sponsor involvement is visible in the biomarker studies and patient-reported work through recurring author affiliations ^8,11,25, as is normal at this stage of development.
10. A large share of the retatrutide literature is reviews of reviews. Of roughly 170 records, the 2026 cohort is heavily weighted toward commentary and synthesis rather than primary data, which inflates apparent evidence volume without adding observations.
11. Fewer than thirty of roughly 170 records were examined, across two searches.
12. This guide has read abstracts, not full texts, for every source cited, and for two sources ^16,28 not even that.

09 · Legal and regulatory appendix

This appendix applies to every compound in this family and is reproduced in each guide.

Approval status. Retatrutide holds no marketing authorisation known to this guide and is described in the peer-reviewed literature as undergoing clinical trials ²⁷. Supplying or administering an unapproved drug for human use is unlawful in the United States and in most other jurisdictions outside an authorised trial or expanded-access pathway. This guide does not describe how to obtain the compound and takes no position on any supplier.

Products sold under this name. Material sold as retatrutide outside a clinical trial has no established relationship to the material used in the studies cited here. A peer-reviewed analysis of such products has been published ²⁸; this guide has not read its findings and reports none. Nothing in the trial evidence described above should be read as applying to any consumer-market product.

Research-use labelling. Material labelled for laboratory research use is not manufactured, tested, or released to the standards applied to medicines intended for people, and such labelling does not make administration lawful or safe.

What this guide is. A description of the published peer-reviewed literature, written for readers who want to understand the state of the evidence. It is not medical advice, not a recommendation, not an endorsement, and not a substitute for a clinician who can assess an individual situation.

Editorial position. Arkham Labs publishes independently and earns through disclosed referral links. That commercial relationship is disclosed on every page carrying such a link and on the editorial standards page. It does not alter what the evidence says, and this guide states plainly that the evidence for this compound is incomplete in ways that matter.

10 · References

1. Winkler G, Kis JT, Arapovicsné Kiss K, Schandl L. [From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism]. Orv Hetil. 2023 Oct 22;164(42):1656–1664. Review. Hungarian.

   PMID 37865924 ↗

2. Bailey CJ, Flatt PR, Conlon JM. Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides. 2024 Mar;173:171149.

   PMID 38184193 ↗

3. Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L, Mantzoros CS. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025 Jan;77(1):100002.

   PMID 39952695 ↗

4. Guo H, Yang J, Huang J, Xu L, Lv Y, Wang Y, Ren J, Feng Y, Zheng Q, Li L. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: a model-based meta-analysis of placebo-controlled trials. Obes Pillars. 2025 Jan 30;13:100162.

   PMID 39980735 ↗

5. Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025 Feb 5;38(3):291–303. Review.

   PMID 40291085 ↗

6. Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025 May;187:171380. Review.

   PMID 40081498 ↗

7. Rodriguez N, Hartmann P. Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease. Pharmacol Rev. 2025 Jul;77(4):100058. Review.

   PMID 40554267 ↗

8. Goetz IA, Kanu C, Hoover A, Jimenez-Moreno C, Karn H, Kimel M, Neff LM, Boye KS. Perceived benefits of treatment for obesity with retatrutide: a qualitative study of patients in a phase 2 clinical trial. Obes Pillars. 2025 Oct 24;16:100220.

   PMID 41216380 ↗

9. Sinha B, Ghosal S. Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a Bayesian NMA. Obesity (Silver Spring). 2025 Nov;33(11):2046–2054.

   PMID 40685589 ↗

10. Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN. IUPHAR review: from foe to friend: repurposing glucagon to treat obesity and type 2 diabetes. Pharmacol Res. 2026 Jan;223:108077. Review.

    PMID 41478576 ↗

11. Kanu C, Kimel M, Goetz I, Neff LM, Boye KS, Stefan M, Jordan J. Development of the Weight and Emotions Scale (WES). Obes Sci Pract. 2026 Jan 25;12(1):e70119.

    PMID 41589220 ↗

12. Briand F, Le Cudennec C, Grasset E, Breyner N, Bigot C, Dillard P, Sulpice T. Retatrutide shows multiple metabolic benefits in diet-induced obese MASH mouse and hamster models. Obesity (Silver Spring). 2026 Jun;34 Suppl 1:43–53.

    PMID 41741376 ↗

13. Wu X, Yang Y, Cui X, Li X, Li Y. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials. Front Pharmacol. 2026 Jun 18;17:1846714.

    PMID 42394981 ↗

14. Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V. Effect of retatrutide, a novel triple receptor agonist, on blood pressure and lipid levels: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev. 2026 Jun 29. Review.

    PMID 42371360 ↗

15. Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026 Jul 8;394:e372161.

    PMID 42419792 ↗

16. Mahase E. Retatrutide fact check: has a man died after taking the unapproved weight loss jab? BMJ. 2026 Jul 9;394:e100245. No abstract available.

    PMID 42425580 ↗

17. Bassatne A, Rizo I. Medical treatments for obesity: what does the future have in store? J Clin Endocrinol Metab. 2026 Jul 14:dgag274.

    PMID 42444567 ↗

18. Tong LH, Leung KK, Hung CT. Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application. J Chromatogr A. 2026 Jul 21;1786:467288.

    PMID 42603384 ↗

19. Koufakis T, Argyrakopoulou G, Kokkinos A, le Roux CW. Retatrutide and the urinary tract infection signal: is the answer hidden in timing? Eur J Intern Med. 2026 Jul 23:107099. No abstract available.

    PMID 42493254 ↗

20. Araiza-Garaygordobil D, Rico-Fontalvo J, Hernández-Balbuena B, Vinay-Coro M, González-Arias M. Incretin analogues as cardiovascular agents: a state-of-the-art review. Front Endocrinol (Lausanne). 2026 Jul 24;17:1898812. Review.

    PMID 42568490 ↗

21. Burmeister MA, Brown SA, Greer JJ, Hoggatt TJ, Zumwalt WT. Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy? Front Endocrinol (Lausanne). 2026 Jul 31;17:1925534. Review.

    PMID 42602523 ↗

22. Bijoch J. Anti-obesity medications in longevity and aesthetic medicine. J Clin Med. 2026 Aug 3;15(15):6026. Review.

    PMID 42590128 ↗

23. Narla S, Narla RR. Integrating GLP-1 receptor agonists into dermatology practice: safety and monitoring strategies. Clin Dermatol. 2026 Aug 6.

    PMID 42562129 ↗

24. Brown C. Retatrutide: obesity drug opens to “compassionate use” in US after speculation Trump took it. BMJ. 2026 Aug 7;394:e100530. No abstract available.

    PMID 42567543 ↗

25. Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ. Retatrutide-associated improvements in cardiovascular risk biomarkers in adults with obesity with or without type 2 diabetes. Diabetes Obes Metab. 2026 Aug 17.

    PMID 42608321 ↗

26. Schifano F, De Luca MA, Bonaccorso S, Arillotta D, Floresta G, Martinotti G, Papanti GD, Corkery JM, Chiappini S, Guirguis A. GLP-1 and dual GIP/GLP-1 receptor agonists’ psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation. Curr Psychiatry Rep. 2026 Aug 21;28(1):65. Review.

    PMID 42624955 ↗

27. Roskoski R Jr. The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity. Pharmacol Res. 2026 Sep;231:108365. Review.

    PMID 42556625 ↗

28. Piatkowski T, Craven A, Cornell S, Ferris J. Composition and labelling accuracy of products sold as retatrutide in Australia. Drug Alcohol Rev. 2026 Sep;45(6):e70231. No abstract available.

    PMID 42559975 ↗

29. Keskin U, Altın E, Kara MK, Tekin B, Çakırçoban KN, Özatik FY, Arı NS, Sezgin AK, Güngor E. Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats. Behav Brain Res. 2026 Oct 2;514:116343.

    PMID 42385950 ↗